J
Juliann Chmielecki
Researcher at AstraZeneca
Publications - 124
Citations - 16230
Juliann Chmielecki is an academic researcher from AstraZeneca. The author has contributed to research in topics: Cancer & Lung cancer. The author has an hindex of 45, co-authored 117 publications receiving 12742 citations. Previous affiliations of Juliann Chmielecki include Massachusetts Institute of Technology & Broad Institute.
Papers
More filters
Journal ArticleDOI
P2.03b-068 The Druggable Mutation Landscape of Lung Adenocarcinoma: Topic: Biomarkers
Anika Gupta,Caitlin F. Connelly,Garrett M. Frampton,Juliann Chmielecki,Siraj M. Ali,James Suh,Alexa B. Schrock,Jeffrey S. Ross,Philip J. Stephens,Vincent A. Miller +9 more
Journal ArticleDOI
Comprehensive genomic profiling of clinically advanced colorectal carcinoma to reveal frequent opportunities for targeted therapies.
Jeffrey S. Ross,Kai Wang,Depinder Khaira,Adrienne Johnson,Juliann Chmielecki,Siraj M. Ali,Julia A. Elvin,Jo-Anne Vergilio,Roman Yelensky,Doron Lipson,Vincent A. Miller,Philip J. Stephens +11 more
TL;DR: Whether comprehensive genomic profiling (CGP) could uncover clinically relevant genomic alterations (CRGA) that could lead to targeted therapy selection is queried.
Journal ArticleDOI
Olaparib maintenance therapy in patients (pts) with platinum-sensitive relapsed (PSR) ovarian cancer (OC) and stable disease (SD) following platinum-based chemotherapy
Amit M. Oza,David Cibula,Ana Oaknin,Christopher J. Poole,Ron H.J. Mathijssen,Gabe S. Sonke,Nicoletta Colombo,J. Špaček,Peter Vuylsteke,H. Hirte,Jacobus Pfisterer,M. Plante,Lars Hanker,Andrew Fielding,V. Haddad,Juliann Chmielecki,Michael Friedlander +16 more
Journal ArticleDOI
Comprehensive genomic profiling of gallbladder adenocarcinoma and frequent genomic-derived targets of therapy.
Phil Stephens,Kai Wang,Norma Alonzo Palma,Juliann Chmielecki,Rachna T. Shroff,Chaitanya Churi,Garrett M. Frampton,Siraj M. Ali,Milind Javle,Jeffrey S. Ross +9 more
TL;DR: A large number of patients diagnosed with GBCA have a poor prognosis and systemic therapies are commonly extrapolated from those used in other gastrointestinal malignancies, but the prognosis is still poor.
Patent
Methods for diagnosing and treating cancer by means of the expression status and mutational status of nrf2 and downstream target genes of said gene.
Christiaan Nicolaas Klijn,James Lee,David Hugh Stokoe,Robert Gentleman,Florian Gnad,Leonard David Goldstein,Juliann Chmielecki,Ryan J. Hartmaier +7 more
TL;DR: In this article, the authors proposed methods of identifying a subject having cancer, such as lung cancer, by analyzing expression levels of one or more NRF2 splice variants or NRF 2 target genes.